Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-196.24%
Shrank
—
—
Shrank
—
1 Year
Score—
Net Growth-196.24%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
3.0
25.49%
40%
—
-100.00%
Never
—
5 Years
Score3.0
Net Growth25.49%
Net Trend40%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
SAB Biotherapeutics Inc fundamental performance
Between 2021 and 2025, revenue declined from $ 60M to $ 0.00 and net income went from -$ 17M to $ 13M. Revenue increased in 0% of the years measured; net income in 40%.
SAB Biotherapeutics Inc currently holds a 5-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 3.80 | — |
1 Year2025-08-12 | $ 2.16 | 75.93% |
5 Years2021-08-12 | $ 99.70 | -96.19% |
All Time2021-02-09 | $ 101.50 | -96.26% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-02-09 |
|---|---|---|---|---|
| Price | $ 3.80 | $ 2.16 | $ 99.70 | $ 101.50 |
| Return | — | 75.93% | -96.19% | -96.26% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 12M | $ 102M |
| 2025 | $ 0.00 | $ 13M | $ 96M |
| 2024 | $ 1M | -$ 34M | $ 20M |
| 2023 | $ 2M | -$ 42M | $ 56M |
| 2022 | $ 23M | -$ 18M | $ 15M |
| IPO2021 | $ 60M | -$ 17M | $ 33M |
Explore beyond SABS
You're looking at SAB Biotherapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
